PedAM
Pediatric Disease Annotations & Medicines
| Disease | progressive multifocal leukoencephalopathy |
| Phenotype | C0026769|multiple sclerosis |
| Sentences | 21 |
| PubMedID- 23323645 | Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy. |
| PubMedID- 25908254 | Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis. |
| PubMedID- 24136456 | progressive multifocal leukoencephalopathy in multiple sclerosis. |
| PubMedID- 24664166 | Importance: infection with jc virus (jcv) may lead to development of demyelinating progressive multifocal leukoencephalopathy in patients with multiple sclerosis (ms) who are treated with natalizumab. |
| PubMedID- 20298967 | Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. |
| PubMedID- 24614671 | Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis. |
| PubMedID- 24852919 | Blood mirna expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. |
| PubMedID- 26394704 | Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. |
| PubMedID- 26190565 | Due to an association of the anti-integrin agent natalizumab with progressive multifocal leukoencephalopathy (pml) in patients with multiple sclerosis (ms), a newly developed anti-jcv antibody assay has been implemented as a risk-stratification tool for natalizumab-treated patients with ms. |
| PubMedID- 24367037 | We report two cases of multiple sclerosis (ms) patients with natalizumab-associated progressive multifocal leukoencephalopathy. |
| PubMedID- 25205744 | Objective: to investigate the mri manifestation pattern of asymptomatic natalizumab-associated progressive multifocal leukoencephalopathy (pml) in patients with multiple sclerosis (ms). |
| PubMedID- 23493158 | progressive multifocal leukoencephalopathy in patients with multiple sclerosis. |
| PubMedID- 24128680 | Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study. |
| PubMedID- 23338729 | Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. |
| PubMedID- 22057786 | Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. |
| PubMedID- 24341880 | Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy. |
| PubMedID- 22054236 | Background and purpose: temporary discontinuation of natalizumab is sometimes considered as the observed risk of progressive multifocal leukoencephalopathy (pml) in patients with multiple sclerosis (ms). |
| PubMedID- 20442571 | Recent findings: natalizumab, a mab targeting the alpha-4 integrins, which is efficient in relapsing-remitting multiple sclerosis, has been associated with progressive multifocal leukoencephalopathy (pml). |
| PubMedID- 25698174 | Objective: the objective of this paper is to estimate the risk of reaching well-established disability milestones after withdrawal of natalizumab (ntz) due to concern about the risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis (ms). |
| PubMedID- 22585288 | Natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis (ms) occurred in two individuals also treated with interferon beta1a, raising concerns about the interaction of these disease-modifying agents and leading to the recommendation to avoid their concomitant administration. |
| PubMedID- 24242357 | Objective: to identify cases of laboratory- or biopsy-confirmed progressive multifocal leukoencephalopathy (pml) in patients with multiple sclerosis (ms) who previously discontinued natalizumab (ntz) for reasons unrelated to suspected or proven pml and assess pml risk factors in these cases. |
Page: 1